GlycA: a novel pro-inflammatory biomarker associated with mortality

  • Gruppen EG & al.
  • J Intern Med
  • 1 Jul 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • GlycA level was associated with increased risk for all-cause mortality in both men and women and with a higher risk for cancer mortality in men only.
  • However, GlycA and high-sensitivity C-reactive protein (hsCRP) levels were not independently associated with cardiovascular (CV) mortality.

Why this matters

  • Previous studies have suggested that GlycA is associated with all-cause mortality in high-risk patients with established cardiovascular disease (CVD) or with several CV risk factors.
  • Published studies on GlycA and all-cause mortality show variable effect sizes.

Study design

  • 5526 patients who participated in the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) were included.
  • The association of GlycA and hsCRP with all-cause, cancer and CV mortality was evaluated across sex-stratified quartile 1 (n=1387), 2 (n=1386), 3 (n=1373) and 4 (n=1380).
  • Funding: None disclosed.

Key results

  • After adjustment for confounders, GlycA was associated with increased risk for all-cause mortality (HR, 1.43; 95% CI, 1.09-1.87; P=.009) among top (1) vs bottom (4) quartile.
  • No significant association was observed in hsCRP level and all-cause mortality (HR, 1.16; 95% CI, 0.88-1.51; P=.29).
  • GlycA (HR, 1.55; 95% CI, 1.03-2.32; P=.034) and hsCRP (HR, 1.71; 95% CI, 1.12-2.61; P=.014) linked to increased risk for cancer mortality in men, but not in women.
  • No significant association was observed between GlycA (HR, 1.05; 0.59-1.89; P=.88) and hsCRP (HR, 0.76; 95% CI, 0.45-1.30; P=.32) and CV mortality.
  • In a meta-analysis of 7 studies, including 8153 deaths, GlycA was associated with higher risk for all-cause mortality (relative risk, 1.74; 95% CI, 1.40-2.17) in top vs bottom quartiles.

Limitations

  • Findings were based on a single baseline measurement of hsCRP and GlycA.
  • Study did not identify underlying causes.